决奈达隆:治疗房颤的新型抗心律失常药  

Dronedarone:a novel antiarrhythmic drug for the treatment of atrial fibrillation

作　　者：刘璟[1] 秦永文[1] 

机构地区：[1]第二军医大学长海医院心血管内科,上海200433

出　　处：《药学服务与研究》2008年第6期417-420,共4页Pharmaceutical Care and Research

摘　　要：决奈达隆为不含碘的苯并呋喃类衍生物,其结构和特征与胺碘酮类似,但减少了碘源性的器官毒性,目前已经完成动物实验和部分临床试验。研究结果表明,在房颤患者中应用决奈达隆800 mg/d安全而有效,不良反应少。Dronedarone is a noniodinated benzofurane derivative, which is structurally and characteristically similar to amiodarone. It has been developed to overcome the iodine-associated adverse effects of amiodarone. The animal experiments and several clinical trials have been accomplished. The clinical trials indicated efficacy,safety and low adverse reactions of dronedarone （800 mg/d） in patients with atrial fibrillation.

关 键 词：决奈达隆 胺碘酮 心房颤动 心律失常 综述 

分 类 号：R972.2[医药卫生—药品]